Extracellular signalling molecules in the ischaemic/reperfused heart - Druggable and translatable for cardioprotection?

British Journal of Pharmacology

Volumn 172, Issue 8, 2015, Pages 2010-2025

  Kleinbongard, P ^a   Heusch, G ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ADENOSINE; ADENOSINE RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; AUTACOID; BRADYKININ; BRADYKININ RECEPTOR; CAPTOPRIL; CREATINE KINASE; CREATINE KINASE MB; CYCLOSPORIN A; CYTOKINE; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; EXENDIN 4; FENTANYL; METOPROLOL; MORPHINE; NATRIURETIC FACTOR; OPIATE; OPIATE RECEPTOR; PLACEBO; SUFENTANIL; TROPONIN I; TROPONIN T; UNINDEXED DRUG; CARDIOTONIC AGENT; LIGAND;

ACUTE HEART INFARCTION; CARDIOPLEGIA; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OCCLUSION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VALVE SURGERY; HUMAN; INTRACORONARY DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANIMAL; CARDIAC MUSCLE; METABOLISM; MYOCARDIAL REPERFUSION INJURY;

ANIMALS; CARDIOTONIC AGENTS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIGANDS; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; SIGNAL TRANSDUCTION;

EID: 84925880426     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12902     Document Type: Review

References (175)

1. Abdel-Wahab M, Khattab AA, Liska B, Kassner G, Geist V, Toelg R, et al. (2008). Diazepam versus fentanyl for premedication during percutaneous coronary intervention: results from the Myocardial Protection by Fentanyl during Coronary Intervention (PROFIT) Trial. J Interv Cardiol 21: 232-238.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Aitchison KA, Baxter GF, Moneeb Awan M, Smith RM, Yellon DM, Opie LH, (2000). Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning. Basic Res Cardiol 95: 1-10.
7. Alkhulaifi AM, Pugsley WB, Yellon DM, (1993). The influence of the time period between preconditioning ischemia and prolonged ischemia on myocardial protection. Cardioscience 4: 163-169.
8. 2+-induced mitochondrial permeability transition. Cardiovasc Res 61: 115-122.
9. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M, (2005). Postconditioning inhibits mitochondrial permeability transition. Circulation 111: 194-197.
10. Auchampach JA, Gross GJ, (1993). Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am J Physiol Heart Circ Physiol 264: H1327-H1336.
11. Barbosa V, Sievers RE, Zaugg CE, Wolfe CL, (1996). Preconditioning ischemia time determines the degree of glycogen depletion and infarct size reduction in rat hearts. Am Heart J 131: 223-230.
12. 1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14: 607-614.
13. Belhomme D, Peynet J, Florens E, Tibourtine O, Kitakaze M, Menasché P, (2000). Is adenosine preconditioning truly cardioprotective in coronary artery bypass surgery ? Ann Thorac Surg 70: 590-594.
14. Bell R, Beeuwkes R, Botker HE, Davidson S, Downey J, Garcia-Dorado D, et al. (2012). Trials, tribulations and speculation! Report from the 7th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 107: 300.
15. Benedetto U, Melina G, Capuano F, Comito C, Bianchini R, Simon C, et al. (2008). Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery. J Cardiovasc Med (Hagerstown) 9: 1098-1103.
16. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, et al. (2008). Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102: 131-135.
17. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R, (2010). Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105: 771-785.
18. Boldt J, Rothe G, Schindler E, Döll C, Görlach G, Hempelmann G, (1996). Can clonidine, enoximone, and enalaprilat help to protect the myocardium against ischaemia in cardiac surgery? Heart 76: 207-213.
19. Bolli R, (2000). The late phase of preconditioning. Circ Res 87: 972-983.
20. Bøtker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, et al. (2010). Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375: 727-734.
21. Braunwald E, (1974). Reduction of myocardial-infarct size. N Engl J Med 5: 525-526.
22. Burley DS, Hamid SA, Baxter GF, (2007). Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev 12: 279-291.
23. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, et al. (2002). The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39: 30-36.
24. Bussmann WD, Micke G, Hildenbrand R, Klepzig H Jr, (1995). Captopril in acute myocardial infarction: beneficial effects on infarct size and arrhythmias. Clin Cardiol 18: 465-470.
25. Cohen MV, Downey JM, (2007). Cardioprotection: spotlight on PKG. Br J Pharmacol 152: 833-834.
26. Cohen MV, Downey JM, (2008). Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103: 203-215.
27. ATP channels. Circ Res 89: 273-278.
28. Cohen MV, Philipp S, Krieg T, Cui L, Kuno A, Solodushko V, et al. (2007). Preconditioning-mimetics bradykinin and DADLE activate PI3-kinase through divergent pathways. J Mol Cell Cardiol 42: 842-851.
29. Costa AD, Garlid KD, (2008). Intramitochondrial signaling-interactions among mitoKATP, PKCe, ROS, and MPT. Am J Physiol Heart Circ Physiol 295: H874-H882.
30. 2A adenosine receptor agonist, reduces myocardial infarct size in a rat ischemia/reperfusion model. Open Cardiovasc Med J 3: 166-172.
31. Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, et al. (2013). Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up. Circ Cardiovasc Interv 6: 246-251.
32. De Luca G, Iorio S, Venegoni L, Marino P, (2012). Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS trial). Am J Cardiol 109: 202-207.
33. De Paulis D, Chiari P, Teixeira G, Couture-Lepetit E, Abrial M, Argaud L, et al. (2013). Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart. Basic Res Cardiol 108: 379.
34. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, et al. (2011). High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 32: 867-877.
35. Deussen A, (2001). Metabolic flux rates of adenosine in the heart. Naunyn Schmiedebergs Arch Pharmacol 362: 351-363.
36. Downey JM, Cohen MV, (2005). We think we see a pattern emerging here. Circulation 111: 120-121.
37. Downey JM, Davis AM, Cohen MV, (2007). Signaling pathways in ischemic preconditioning. Heart Fail Rev 12: 181-188.
38. Downey JM, Krieg T, Cohen MV, (2008). Mapping preconditioning's signaling pathways: an engineering approach. Ann N Y Acad Sci 1123: 187-196.
39. ATP channel opening. Am J Physiol Heart Circ Physiol 284: H1592-H1600.
40. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R, (2014). Interaction of cardiovascular risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning: an update. Pharmacol Rev 66: 1142-1174.
41. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ, et al. (2009). Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv 2: 323-329.
42. Forman MB, Stone GW, Jackson EK, (2006). Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 24: 116-147.
43. Garcia-Dorado D, Otaegui I, Rodriguez Palmoares JF, Evangelista A, Pineda V, Ruiz Salmeron R, et al. (2013). Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI. Eur Heart J 34: 669-670.
44. Gedik N, Heusch G, Skyschally A, (2013). Infarct size reduction by cyclosporine A at reperfusion involves inhibition of the mitochondrial permeability transition pore but does not improve mitochondrial respiration. Arch Med Sci 9: 968-975.
45. Ginks WR, Sybers HD, Maroko PR, Covell JW, Sobel BE, Ross J Jr, (1972). Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest 51: 2717-2723.
46. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM, (1995). Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77: 611-621.
47. Gross ER, Hsu AK, Gross GJ, (2009). Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg 109: 1395-1402.
48. Gross GJ, (2003). Role of opioids in acute and delayed preconditoning. J Mol Cell Cardiol 35: 709-718.
49. Grube K, Rudebusch J, Xu Z, Böckenholt T, Methner C, Müller T, et al. (2011). Evidence for an intracellular localization of the adenosine A(2B) receptor in rat cardiomyocytes. Basic Res Cardiol 106: 385-396.
50. Grygier M, Araszkiewicz A, Lesiak M, Janus M, Kowal J, Skorupski W, et al. (2011). New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 107: 1131-1135.
51. Guo HT, Zhang RH, Zhang Y, Zhang LJ, Li J, Shi QX, et al. (2011). Endogenous kappa-opioid peptide mediates the cardioprotection induced by ischemic postconditioning. J Cardiovasc Pharmacol 58: 207-215.
52. Hausenloy D, Kunst G, Boston-Griffiths E, Kolvekar S, Chaubey S, John L, et al. (2014). The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart 100: 544-549.
53. Hausenloy DJ, Yellon DM, (2004). New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61: 448-460.
54. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM, (2002). Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55: 534-543.
55. Hausenloy DJ, Mocanu MM, Yellon DM, (2004a). Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 63: 305-312.
56. Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR, (2004b). Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 287: H841-H849.
57. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, et al. (2007). Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. Lancet 370: 575-579.
58. Hausenloy DJ, Iliodromitis EK, Andreadou I, Papalois A, Gritsopoulos G, Anastasiou-Nana M, et al. (2012). Investigating the signal transduction pathways underlying remote ischemic conditioning in the porcine heart. Cardiovasc Drugs Ther 26: 87-93.
59. Hausenloy DJ, Bøtker HE, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, et al. (2013). Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 98: 7-27.
60. Heinzel FR, Luo Y, Li X, Boengler K, Buechert A, García-Dorado D, et al. (2005). Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ Res 97: 583-586.
61. Heusch G, (2004). Postconditioning. Old wine in a new bottle? J Am Coll Cardiol 44: 1111-1112.
62. Heusch G, (2008). Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153: 1589-1601.
63. Heusch G, (2010). Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve. Basic Res Cardiol 105: 1-5.
64. Heusch G, (2012). Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? Eur Heart J 33: 13-15.
65. Heusch G, (2013a). Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381: 166-175.
66. Heusch G, (2013b). Remote conditioning: the future of cardioprotection? J Cardiovasc Med (Hagerstown) 14: 176-179.
67. Heusch G, Boengler K, Schulz R, (2008). Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118: 1915-1919.
68. Heusch G, Boengler K, Schulz R, (2010). Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res Cardiol 105: 151-154.
69. Heusch G, Kleinbongard P, Skyschally A, Levkau B, Schulz R, Erbel R, (2012). The coronary circulation in cardioprotection: more than just one confounder. Cardiovasc Res 94: 237-245.
70. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, et al. (2014). Cardiovascular remodeling in coronary artery disease and heart failure. Lancet 383: 1933-1943.
71. Homeister JW, Hoff PT, Fletcher DD, Lucchesi BR, (1990). Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation 82: 595-608.
72. Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, et al. (2013). Effect of early metoprolol on infarct size in ST-segment elevation myocardial infarction patients undergoing primary PCI: the METOCARD-CNIC Trial. Circulation 128: 1495-1503.
73. Ikeda Y, Miura T, Sakamoto J, Miki T, Tonno M, Kobayashi H, et al. (2006). Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by delta-opioid receptor activation. Basic Res Cardiol 101: 418-426.
74. Jakobsen O, Naesheim T, Aas KN, Sorlie D, Steensrud T, (2013). Adenosine instead of supranormal potassium in cardioplegia: it is safe, efficient, and reduces the incidence of postoperative atrial fibrillation. A randomized clinical trial. J Thorac Cardiovasc Surg 145: 812-818.
75. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32: 1787-1796.
76. Jalowy A, Schulz R, Heusch G, (1999). AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol 10: S129-S139.
77. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z, (2008). Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 108: 243-250.
78. Jin ZX, Zhou JJ, Xin M, Peng DR, Wang XM, Bi SH, et al. (2007). Postconditioning the human heart with adenosine in heart valve replacement surgery. Ann Thorac Surg 83: 2066-2072.
79. Juhaszova M, Zorov DB, Kim S-H, Pepe S, Fu Q, Fishbein KW, et al. (2004). Glycogen synthase kinase-3ß mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549.
80. Kato R, Foex P, (2002). Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. Can J Anaesth 49: 777-791.
81. Kato R, Ross S, Foex P, (2000). Fentanyl protects the heart against ischaemic injury via opioid receptors, adenosine A1 receptors and KATP channel linked mechanisms in rats. Br J Anaesth 84: 204-214.
82. Kim SJ, Kim W, Woo JS, Ha SJ, Kang WY, Hwang SH, et al. (2012). Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial. Int J Cardiol 158: 88-92.
83. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, et al. (2005). Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67: 124-133.
84. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. (2007). Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370: 1483-1493.
85. Kleinbongard P, Böse D, Baars T, Möhlenkamp S, Konorza T, Schöner S, et al. (2011). Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 108: 344-352.
86. Kloner RA, (2013). Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res 113: 451-463.
87. Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, Kovanen PT, (1999). Kallidin- and bradykinin-degrading pathways in human heart. Circulation 99: 1984-1990.
88. Kokkonen JO, Lindstedt KA, Kuoppala A, Kovanen PT, (2000). Kinin-degrading pathways in the human heart. Trends Cardiovasc Med 10: 42-45.
89. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G, et al. (2003). A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 146: 146-152.
90. Kurz T, Schäfer U, Dendorfer A, Hartmann F, Raasch W, Tölg R, et al. (2001). Effects of intracoronary low-dose enalaprilat as an adjunct to primary percutaneous transluminal coronary angiography in acute myocardial infarction. Am J Cardiol 88: 1351-1357.
91. Kuzmin AI, Gourine AV, Molosh AI, Lakomkin VL, Vassort G, (2000). Effects of preconditioning on myocardial interstitial levels of ATP and its catabolites during regional ischemia and reperfusion in the rat. Basic Res Cardiol 95: 127-136.
92. Lasley RD, Konyn PJ, Hegge JO, Mentzer RM Jr, (1995). Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Am J Physiol Heart Circ Physiol 38: H1460-H1466.
93. Lecour S, (2009). Multiple protective pathways against reperfusion injury: a SAFE path without Aktion? J Mol Cell Cardiol 46: 607-609.
94. Lee CH, Low A, Tai BC, Co M, Chan MY, Lim J, et al. (2007). Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study. Eur Heart J 28: 19-25.
95. Li Y, Kloner RA, (1993). The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts. Circulation 87: 1642-1648.
96. Linz W, Wiemer G, Scholkens BA, (1997). Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol 80: 118A-123A.
97. Liu GS, Thornton J, van Winkle DM, Stanley AWH, Olsson RA, Downey JM, (1991). Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84: 350-356.
98. Liu GS, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM, (1994). Evidence that adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 28: 1057-1061.
99. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, et al. (2012). Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 5: 288-295.
100. Mahaffey KW, Puma JA, Barbagelata A, DiCarli MF, Leesar MA, Browne KF, et al. (1999). Adenosine as an adjunct thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 34: 1711-1720.
101. Mangiacapra F, Peace AJ, Di SL, Pyxaras SA, Bartunek J, Wyffels E, et al. (2013). Intracoronary enalaprilat to reduce microvascular damage during percutaneous coronary intervention (ProMicro) study. J Am Coll Cardiol 61: 615-621.
102. Maroko PR, Libby P, Ginks WR, Bloor CM, Shell WE, Sobel BE, et al. (1972). Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest 51: 2710-2716.
103. Marzilli M, Orsini E, Marraccini P, Testa R, (2000). Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101: 2154-2159.
104. McAlister FA, (2012). Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J 33: 505-514.
105. McCully JD, Toyoda Y, Uematsu M, Stewart RD, Levitsky S, (2001). Adenosine-enhanced ischemic preconditioning: adenosine receptor involvement during ischemia and reperfusion. Am J Physiol Heart Circ Physiol 280: H591-H602.
106. McIntosh VJ, Lasley RD, (2012). Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther 17: 21-33.
107. ATP channel opener: effects on interstitial adenosine in dogs. J Mol Cell Cardiol 30: 1225-1236.
108. Methner C, Schmidt K, Cohen MV, Downey JM, Krieg T, (2010). Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 299: H1262-H1264.
109. Methner C, Lukowski R, Grube K, Loga F, Smith RA, Murphy MP, et al. (2013). Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 108: 337.
110. Miki T, Cohen MV, Downey JM, (1998). Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem 186: 3-12.
111. Murry CE, Jennings RB, Reimer KA, (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.
112. Mustafa SJ, Morrison RR, Teng B, Pelleg A, (2009). Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 193: 161-188.
113. Neuhäuser C, Preiss V, Feurer MK, Müller M, Scholz S, Kwapisz M, et al. (2008). Comparison of S-(+)-ketamine- with sufentanil-based anaesthesia for elective coronary artery bypass graft surgery: effect on troponin T levels. Br J Anaesth 100: 765-771.
114. Newman MF, Ferguson TB, White JA, Ambrosio G, Koglin J, Nussmeier NA, et al. (2012). Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA 308: 157-164.
115. Obame FN, Zini R, Souktani R, Berdeaux A, Morin D, (2007). Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J Pharmacol Exp Ther 323: 336-345.
116. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. (2010). Postconditioning and protection from reperfusion injury: where do we stand? Cardiovasc Res 87: 406-423.
117. ATP channels triggers the preconditioned state by generating free radicals. Circ Res 87: 460-466.
118. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-1106.
119. Peart JN, Gross ER, Gross GJ, (2005). Opioid-induced preconditioning: recent advances and future perspectives. Vascul Pharmacol 42: 211-218.
120. Penna C, Mancardi D, Tullio F, Pagliaro P, (2008). Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 103: 368-377.
121. Penna C, Perrelli MG, Tullio F, Angotti C, Camporeale A, Poli V, et al. (2013). Diazoxide postconditioning induces mitochondrial protein S-Nitrosylation and a redox-sensitive mitochondrial phosphorylation/translocation of RISK elements: no role for SAFE. Basic Res Cardiol 108: 371.
122. 2b receptor cascade. Cardiovasc Res 70: 308-314.
123. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. (2008). Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481.
124. Pizarro G, Fernandez-Friera L, Fuster V, Fernandez-Jimenez R, Garcia-Ruiz JM, Garcia-Alvarez A, et al. (2014). Long term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial. J Am Coll Cardiol 63: 2356-2362.
125. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P, (1993). Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87: 893-899.
126. Pugsley MK, (2002). The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system. Pharmacol Ther 93: 51-75.
127. Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M, (2014). Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res 114: 1601-1610.
128. Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, et al. (2010). Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv 3: 49-55.
129. Rinne T, Laurikka J, Penttila I, Kaukinen S, (2000). Adenosine with cold blood cardioplegia during coronary revascularization. J Cardiothorac Vasc Anesth 14: 18-20.
130. Ross A, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, (2005). A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD II). J Am Coll Cardiol 45: 1775-1780.
131. Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, et al. (2013). A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 61: 131-142.
132. Saxena P, Aggarwal S, Misso NL, Passage J, Newman MA, Thompson PJ, et al. (2013). Remote ischaemic preconditioning down-regulates kinin receptor expression in neutrophils of patients undergoing heart surgery. Interact Cardiovasc Thorac Surg 17: 653-658.
133. Schoemaker RG, van Heijningen CL, (2000). Bradykinin mediates cardiac preconditioning at a distance. Am J Physiol Heart Circ Physiol 278: H1571-H1576.
134. Schultz JEJ, Hsu AK, Gross GJ, (1998). Ischemic preconditioning in the intact rat heart is mediated by d1- but not m- or k- opioid receptors. Circulation 97: 1282-1289.
135. Schultz JEL, Rose E, Yao Z, Gross GJ, (1995). Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 268: H2157-H2161.
136. Schulz R, Rose J, Post H, Heusch G, (1995). Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflugers Arch 430: 273-282.
137. Schulz R, Post H, Vahlhaus C, Heusch G, (1998). Ischemic preconditioning in pigs: a graded phenomenon. Its relation to adenosine and bradykinin. Circulation 98: 1022-1029.
138. Schulz R, Gres P, Heusch G, (2001). Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs. Am J Physiol Heart Circ Physiol 280: H2175-H2181.
139. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, et al. (2011). New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 124: 1172-1179.
140. Shariff N, Dunbar C, Matsumura ME, (2010). Relation of pre-event use of inhibitors of the renin-angiotensin system with myocardial infarct size in patients presenting with a first ST-segment elevation myocardial infarction. Am J Cardiol 106: 646-649.
141. Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, et al. (2009). Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond) 117: 191-200.
142. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, et al. (2009). Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104: 15-18.
143. Skyschally A, Schulz R, Heusch G, (2010). Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 24: 85-87.
144. Slogoff S, Keats AS, (1989). Randomized trial of primary anesthetic agents on outcome of coronary artery bypass operations. Anesthesiology 70: 179-188.
145. Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, et al. (2014). Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 35: 168-175.
146. Stein AB, Tang X-L, Guo Y, Xuan Y-T, Dawn B, Bolli R, (2004). Delayed adaptation of the heart to stress. Late preconditioning. Stroke 35: 2676-2679.
147. Suzuki K, Miura T, Miki T, Tsuchida A, Shimamoto K, (1998). Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. J Cardiovasc Pharmacol 31: 1-9.
148. Teoh LKK, Grant R, Hulf JA, Pugsley WB, Yellon DM, (2002). The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc Res 53: 175-180.
149. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, et al. (2010). Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 105: 657-664.
150. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, et al. (2013). Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382: 597-604.
151. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, et al. (2009). Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510.
152. Tullio F, Angotti C, Perrelli MG, Penna C, Pagliaro P, (2013). Redox balance and cardioprotection. Basic Res Cardiol 108: 392.
153. Tuman KJ, McCarthy RJ, Spiess BD, DaValle M, Dabir R, Ivankovich AD, (1989). Does choice of anesthetic agent significantly affect outcome after coronary artery surgery? Anesthesiology 70: 189-198.
154. Vahlhaus C, Schulz R, Post H, Onallah R, Heusch G, (1996). No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res 79: 407-414.
155. Vahlhaus C, Schulz R, Post H, Rose J, Heusch G, (1998). Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol 30: 197-209.
156. Vander Heide RS, Reimer KA, (1996). Effect of adenosine therapy at reperfusion and myocardial infarct size in dogs. Cardiovasc Res 31: 711-718.
157. Wall TM, Sheehy R, Hartman JC, (1994). Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 2: 681-689.
158. Walter T, Helber U, Bail D, Heller W, Hoffmeister HM, (2002). Influence of ACE inhibition on myocardial damage, the kallikrein-kinin system and hemostasis during cardiopulmonary bypass surgery. Thorac Cardiovasc Surg 50: 150-154.
159. Wang Q, Sun Y, Li J, Xing W, Zhang S, Gu X, et al. (2014). Quaternary ammonium salt of U50488H, a new kappa-opioid receptor agonist, protects rat heart against ischemia/reperfusion injury. Eur J Pharmacol 737C: 177-184.
160. Wang X, Wei M, Kuukasjärvi P, Laurikka J, Rinne T, Moilanen E, et al. (2009). The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning). Scand Cardiovasc J 43: 72-79.
161. Wei M, Wang X, Kuukasjärvi P, Laurikka J, Rinne T, Honkonen EL, et al. (2004). Bradykinin preconditioning in coronary artery bypass grafting. Ann Thorac Surg 78: 492-497.
162. 1-receptor antagonism. Br J Pharmacol 131: 138-144.
163. van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF, (1994). Cardioprotection provided by adenosine receptor activation is abolished by blockade of the K-ATP channel. Am J Physiol 266: H829-H839.
164. Wong GT, Huang Z, Ji S, Irwin MG, (2010a). Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth 24: 790-796.
165. Wong GT, Li R, Jiang LL, Irwin MG, (2010b). Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand 54: 510-518.
166. Xi J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H, et al. (2009). Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 47: 684-690.
167. Xin W, Yang X, Rich TC, Krieg T, Barrington R, Cohen MV, et al. (2012). All preconditioning-related g protein-coupled receptors can be demonstrated in the rabbit cardiomyocyte. J Cardiovasc Pharmacol Ther 17: 190-198.
168. Xu Z, Yang X-M, Cohen MV, Neumann T, Heusch G, Downey JM, (2000). Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist 579 administerd at reperfusion. J Mol Cell Cardiol 32: 2339-2347.
169. Yellon DM, Downey JM, (2003). Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113-1151.
170. Yellon DM, Hausenloy DJ, (2007). Myocardial reperfusion injury. N Engl J Med 357: 1121-1135.
171. Younes A, Pepe S, Yoshishige D, Caffrey JL, Lakatta EG, (2005). Ischemic preconditioning increases the bioavailability of cardiac enkephalins. Am J Physiol Heart Circ Physiol 289: H1652-H1661.
172. Zatta AJ, Kin H, Yoshishige D, Jiang R, Wang N, Reeves JG, et al. (2008). Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 294: H1444-H1451.
173. Zaugg M, Lucchinetti E, Behmanesh S, Clanachan AS, (2014). Anesthetic cardioprotection in clinical practice from proof-of-concept to clinical applications. Curr Pharm Des 20: 5706-5726.
174. Zhang H, Tian NL, Hu ZY, Wang F, Chen L, Zhang YJ, et al. (2012). Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 125: 1713-1719.
175. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA, et al. (2003). Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-H588.